An insurance benefit that provides percutaneous coronary intervention patients with a discharge supply of antiplatelet medication could result in cost savings for insurers.
Michael P. Dorsch, PharmD, MS
Advertisement
Articles by Michael P. Dorsch, PharmD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5